MXPA03008755A - Derivados de 2-amino-propanol. - Google Patents

Derivados de 2-amino-propanol.

Info

Publication number
MXPA03008755A
MXPA03008755A MXPA03008755A MXPA03008755A MXPA03008755A MX PA03008755 A MXPA03008755 A MX PA03008755A MX PA03008755 A MXPA03008755 A MX PA03008755A MX PA03008755 A MXPA03008755 A MX PA03008755A MX PA03008755 A MXPA03008755 A MX PA03008755A
Authority
MX
Mexico
Prior art keywords
amino
propanol derivatives
compounds
propanol
derivatives
Prior art date
Application number
MXPA03008755A
Other languages
English (en)
Inventor
Volker Brinkmann
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0107506A external-priority patent/GB0107506D0/en
Priority claimed from GB0107507A external-priority patent/GB0107507D0/en
Priority claimed from GB0108346A external-priority patent/GB0108346D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MXPA03008755A publication Critical patent/MXPA03008755A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/6574—Esters of oxyacids of phosphorus
    • C07F9/65744—Esters of oxyacids of phosphorus condensed with carbocyclic or heterocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/64—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/02—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C225/14—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being unsaturated
    • C07C225/16—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/16—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/094—Esters of phosphoric acids with arylalkanols
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/113—Esters of phosphoric acids with unsaturated acyclic alcohols
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/12—Esters of phosphoric acids with hydroxyaryl compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

Los compuestos de la formula I: (ver formula) en donde m, R, R1, y R3 a R6 son como se definen en la memoria descriptiva, m es 1, 2, o 3, y X es O o un enlace directo, y los compuestos no fosforilados correspondientes, tienen propiedades interesantes, por ejemplo propiedades inmunosupresoras.
MXPA03008755A 2001-03-26 2002-03-26 Derivados de 2-amino-propanol. MXPA03008755A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0107506A GB0107506D0 (en) 2001-03-26 2001-03-26 Organic compounds
GB0107507A GB0107507D0 (en) 2001-03-26 2001-03-26 Organic compounds
GB0108346A GB0108346D0 (en) 2001-04-03 2001-04-03 Organic compounds
PCT/EP2002/003389 WO2002076995A2 (en) 2001-03-26 2002-03-26 2-amino-propanol derivatives

Publications (1)

Publication Number Publication Date
MXPA03008755A true MXPA03008755A (es) 2004-02-18

Family

ID=27256123

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03008755A MXPA03008755A (es) 2001-03-26 2002-03-26 Derivados de 2-amino-propanol.

Country Status (18)

Country Link
US (1) US7326801B2 (es)
EP (1) EP1377593B1 (es)
JP (1) JP4012823B2 (es)
KR (1) KR20030093279A (es)
CN (1) CN1620461A (es)
AT (1) ATE314383T1 (es)
BR (1) BR0208365A (es)
CA (1) CA2442178A1 (es)
CZ (1) CZ20032560A3 (es)
DE (1) DE60208355T2 (es)
DK (1) DK1377593T3 (es)
ES (1) ES2254675T3 (es)
IL (1) IL157773A0 (es)
MX (1) MXPA03008755A (es)
NO (1) NO20034291L (es)
PL (1) PL367348A1 (es)
SK (1) SK11942003A3 (es)
WO (1) WO2002076995A2 (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0306811A (pt) 2002-01-11 2004-10-26 Sankyo Co Composto, éster farmacologicamente aceitável do mesmo, composição farmacêutica e métodos para prevenção ou tratamento de doenças autoimunes, da artrite reumatóide e da rejeição causada pelo transplante de vários órgãos em um mamìfero
CA2483594C (en) 2002-05-16 2011-02-15 Novartis Ag Use of edg receptor binding agents in cancer
GB0217152D0 (en) 2002-07-24 2002-09-04 Novartis Ag Organic compounds
EP1546110A4 (en) 2002-07-30 2008-03-26 Univ Virginia ACTIVE COMPOUNDS IN THE SIGNALING OF SPHINGOSINE 1-PHOSPHATE
EP1539674A1 (en) * 2002-09-13 2005-06-15 Novartis AG Amino-propanol derivatives
EP2617711A1 (en) * 2002-09-19 2013-07-24 Kyorin Pharmaceutical Co., Ltd. Amino alcohol derivatives, salts thereof and immunosuppressive agents
US20060046979A1 (en) 2002-09-24 2006-03-02 Foster Carolyn A Organic compounds
EP1594508B1 (en) * 2003-02-11 2012-08-08 Irm Llc Novel bicyclic compounds and compositions
KR101005171B1 (ko) 2003-02-18 2011-01-04 교린 세이야꾸 가부시키 가이샤 아미노포스폰산 유도체와 그 부가염 및 ｓ1ｐ 수용체조절제
PL2316431T3 (pl) 2003-04-08 2016-09-30 Kompozycja w postaci stałego preparatu do stosowania doustnego obejmująca agonistę receptora S1P i alkohol cukrowy
BRPI0410025A (pt) 2003-04-30 2006-04-25 Novartis Ag derivados de amino-propanol como modulador do receptor de esfingosina-1-fosfato
AU2004234067B2 (en) * 2003-04-30 2008-02-28 Novartis Ag Aminopropanol derivatives as sphingosine-1-phosphate receptor modulators
GB0313612D0 (en) 2003-06-12 2003-07-16 Novartis Ag Organic compounds
CN102175786B (zh) * 2003-08-28 2013-07-17 诺瓦提斯公司 氨基丙醇衍生物
GB0320638D0 (en) 2003-09-03 2003-10-01 Novartis Ag Organic compounds
WO2005041899A2 (en) 2003-11-03 2005-05-12 University Of Virginia Patent Foundation Orally available sphingosine 1-phosphate receptor agonists and antagonists
JPWO2005044780A1 (ja) * 2003-11-10 2007-05-17 杏林製薬株式会社 アミノカルボン酸誘導体とその付加塩及びｓ１ｐ受容体調節剤
GB0329498D0 (en) * 2003-12-19 2004-01-28 Novartis Ag Organic compounds
GB0500020D0 (en) 2005-01-04 2005-02-09 Novartis Ag Organic compounds
AU2005215320B2 (en) 2004-02-24 2008-04-17 Sankyo Company, Limited Amino alcohol compound
GB0405289D0 (en) * 2004-03-09 2004-04-21 Novartis Ag Organic compounds
CA2563569A1 (en) * 2004-05-03 2005-11-10 Novartis Ag Combinations comprising a s1p receptor agonist and a jak3 kinase inhibitor
GB0411929D0 (en) 2004-05-27 2004-06-30 Novartis Ag Organic compounds
EP1772145B1 (en) 2004-07-16 2011-03-23 Kyorin Pharmaceutical Co., Ltd. Method of effectively using medicine and method concerning prevention of side effect
MX2007001236A (es) 2004-07-30 2007-03-23 Novartis Ag Formulaciones de compuestos de 2-amino-1, 3-propanodiol.
US7241812B2 (en) 2004-08-13 2007-07-10 Praecis Pharmaceuticals, Inc. Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity
JP4792400B2 (ja) * 2004-10-12 2011-10-12 杏林製薬株式会社 ２−アミノ−２−［２−［４−（３−ベンジルオキシフェニルチオ）−２−クロロフェニル］エチル］−１，３−プロパンジオール塩酸塩又はその水和物の製造方法及びその製造中間体
EP2384749A1 (en) 2004-11-29 2011-11-09 Novartis AG Dosage regimen of an S1P receptor agonist
JP2008530135A (ja) 2005-02-14 2008-08-07 ユニバーシティ オブ バージニア パテント ファンデーション アミノ基およびフェニル基で置換されたシクロアルカンならびに５員の複素環を含むスフィンゴシン＝１−リン酸アゴニスト
GB0504544D0 (en) * 2005-03-04 2005-04-13 Novartis Ag Organic compounds
EA013816B1 (ru) 2005-09-01 2010-08-30 Арес Трейдинг С.А. Лечение неврита зрительного нерва
WO2007043433A1 (ja) * 2005-10-07 2007-04-19 Kyorin Pharmaceutical Co., Ltd. ２－アミノ－１，３－プロパンジオール誘導体を有効成分とする肝臓疾患治療剤および肝臓疾患治療方法
CN101346346B (zh) * 2005-12-15 2012-08-22 田边三菱制药株式会社 胺化合物及其医药用途
AU2007209961A1 (en) 2006-01-27 2007-08-09 University Of Virginia Patent Foundation Method for treatment of neuropathic pain
TWI389683B (zh) * 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
JP2009526073A (ja) 2006-02-09 2009-07-16 ユニバーシティ オブ バージニア パテント ファンデーション 二環式スフィンゴシン−１−リン酸受容体アナログ
KR101059593B1 (ko) 2006-04-11 2011-08-25 노파르티스 아게 Ｈｃｖ/ｈｉｖ 억제제 및 이들의 용도
DK2058317T3 (da) * 2006-08-08 2014-01-06 Kyorin Seiyaku Kk Aminophosphorsyreesterderivat og S1P receptormodulator indeholdende samme som aktiv ingrediens
TWI396677B (zh) 2006-08-08 2013-05-21 Kyorin Seiyaku Kk An amine alcohol derivative and an immunosuppressive agent for use as an active ingredient
AU2007323557A1 (en) 2006-11-21 2008-05-29 University Of Virginia Patent Foundation Benzocycloheptyl analogs having sphingosine 1-phosphate receptor activity
EP2097397A1 (en) 2006-11-21 2009-09-09 University Of Virginia Patent Foundation Tetralin analogs having sphingosine 1-phosphate agonist activity
EP2099741A2 (en) 2006-11-21 2009-09-16 University Of Virginia Patent Foundation Hydrindane analogs having sphingosine 1-phosphate receptor agonist activity
TWI439263B (zh) 2007-06-14 2014-06-01 Mitsubishi Tanabe Pharma Corp 胺化合物及其醫藥用途
US8476305B2 (en) * 2008-02-07 2013-07-02 Kyorin Pharmaceutical Co., Ltd. Therapeutic agent or prophylactic agent for inflammatory bowel disease comprising amino alcohol derivative as active ingredient
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
BR112013008510A2 (pt) 2010-10-08 2016-07-05 Novartis Ag vitamina e formulações de inibidores de sulfamida ns3
GB201715786D0 (en) 2017-09-29 2017-11-15 Univ College Cardiff Consultants Ltd Compounds

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2126658T3 (es) * 1992-10-21 1999-04-01 Yoshitomi Pharmaceutical Compuesto de 2-amino-1,3-propanodiol e inmunosupresor.
ES2065855B1 (es) * 1993-05-31 1995-09-01 Menarini Lab Procedimiento para la preparacion de nuevos derivados desoxiazafosfolipidicos con accion inhibidora de la fosfolipasa a2, nuevos derivados desoxiazafosfolipidicos obtenidos y utilizacion de los mismos.
PT778263E (pt) * 1994-08-22 2002-06-28 Mitsubishi Pharma Corp Composto de benzeno e sua utilizacao farmaceutica
EP1319651B1 (en) * 1997-04-04 2005-06-29 Mitsubishi Pharma Corporation 2-Aminopropane-1,3-diol compound, pharmaceutical use thereof and synthetic intermediates therefor
EP1300405B1 (en) 2000-07-13 2007-04-18 Sankyo Company, Limited Amino alcohol derivatives
JP2004507552A (ja) * 2000-08-31 2004-03-11 メルク　エンド　カムパニー　インコーポレーテッド 免疫調節剤としてのリン酸誘導体

Also Published As

Publication number Publication date
SK11942003A3 (sk) 2004-03-02
EP1377593B1 (en) 2005-12-28
PL367348A1 (en) 2005-02-21
ES2254675T3 (es) 2006-06-16
IL157773A0 (en) 2004-03-28
JP4012823B2 (ja) 2007-11-21
DE60208355T2 (de) 2006-07-27
BR0208365A (pt) 2004-03-09
DK1377593T3 (da) 2006-04-10
NO20034291D0 (no) 2003-09-25
WO2002076995A3 (en) 2003-02-13
NO20034291L (no) 2003-11-24
CZ20032560A3 (cs) 2003-12-17
US20040147490A1 (en) 2004-07-29
US7326801B2 (en) 2008-02-05
EP1377593A2 (en) 2004-01-07
CN1620461A (zh) 2005-05-25
KR20030093279A (ko) 2003-12-06
ATE314383T1 (de) 2006-01-15
WO2002076995A2 (en) 2002-10-03
CA2442178A1 (en) 2002-10-03
JP2004531501A (ja) 2004-10-14
DE60208355D1 (de) 2006-02-02

Similar Documents

Publication Publication Date Title
MXPA03008755A (es) Derivados de 2-amino-propanol.
AU7278500A (en) Fungicides
CA2352505A1 (en) Epothilone derivatives and their use as antitumor agents
AU5414000A (en) Compounds
AU6645998A (en) Oxygen or sulfur containing heteroaromatics as factor xa inhibitors
AP2002002637A0 (en) Novel piperazine
HK1087022A1 (en) Dpp-iv inhibitors
WO2002032898A3 (de) Neue anticholinergika, verfahren zu deren herstellung und deren verwendung als arzneimittel
WO2003006425A3 (en) Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
HK1071510A1 (en) Acetylene derivatives having mglur 5 antagonistic activity
CA2408602A1 (en) Phenylglycine derivatives
GB9929552D0 (en) Compounds
AU4064597A (en) Amidinophenyl-pyrrolidines, -pyrrolines, and -isoxazolidines and derivatives thereof
GB0011203D0 (en) Chemical compounds
GB0114185D0 (en) Compounds
WO2001055066A3 (en) 3-phenoxy-1-phenyl acetylene derivatives and their use as herbicides
SE0004245D0 (sv) Novel compounds and their use
YU78303A (sh) Postupak za dobijanje 1,3-supstituisanih indena i azapolicikličnih jedinjenja sa pripojenim arilom
MY133969A (en) Indoloquinazolinones
WO2002032901A3 (en) Bridged piperazine derivatives
AU7027100A (en) Novel compounds
CA2309474A1 (en) New 4-arylpiperidine derivatives for the treatment of pruritus
AU6339000A (en) Serotonergic benzothiophenes
WO2001009122A3 (en) Serotonergic benzofurans
IL148161A0 (en) Process for the preparation of 2-cyanopyridines